<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910429-0017</DOCNO><DOCID>910429-0017.</DOCID><HL>   Wyeth-Ayerst Starts Fund   To Help Norplant Buyers</HL><DATE>04/29/91</DATE><SO>WALL STREET JOURNAL (J), PAGE A8</SO><CO>   AHP</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><RE>NEW YORK (NY)</RE><LP>   PHILADELPHIA -- Wyeth-Ayerst Laboratories, which has comeunder fire for the $350 price of its new contraceptive,Norplant, said it had established a foundation funded at $2.8million to disburse the device to women who can't afford it.   Health-care groups that praised the move nonethelessremained steadfast in their demands that Wyeth-Ayerst, a unitof New York-based American Home Products Corp., offer a lowerprice to public agencies for the contraceptive. The companyhas enraged health-care officials in various states who sayNorplant appears to be the first contraceptive not to be soldat traditional steep discounts to public health departments,thus curtailing availability to millions of women.</LP><TEXT>   Health professionals are reporting that many women ruleout Norplant as an option because they can't afford the sixmatchstick-sized silicone rubber capsules, Dennis Barbour,president of the Association of Reproductive HealthProfessionals, said. When implanted in a woman's upper arm,it gradually releases a hormone that can protect againstpregnancy for up to five years. Norplant, developed withpublic funds, is sold in other countries under a marketingagreement with a Finnish company for as low as $23.</TEXT></DOC>